litlas
Log inCreate account

Keith Wheatley

Active 1988–2025

122
Papers
36,378
Citations
89
h-index
119
i10-index

Citations

Citations per year for Keith Wheatley1977: 2 citations1978: 5 citations1979: 7 citations1980: 5 citations1981: 3 citations1982: 3 citations1983: 10 citations1984: 10 citations1985: 12 citations1986: 13 citations1987: 8 citations1988: 10 citations1989: 24 citations1990: 13 citations1991: 15 citations1992: 25 citations1993: 15 citations1994: 14 citations1995: 30 citations1996: 42 citations1997: 67 citations1998: 86 citations1999: 103 citations2000: 114 citations2001: 159 citations2002: 220 citations2003: 252 citations2004: 202 citations2005: 274 citations2006: 270 citations2007: 269 citations2008: 278 citations2009: 311 citations2010: 309 citations2011: 313 citations2012: 356 citations2013: 317 citations2014: 334 citations2015: 288 citations2016: 294 citations2017: 209 citations2018: 220 citations2019: 819 citations2020: 694 citations2021: 744 citations2022: 422 citations2023: 352 citations2024: 497 citations2025: 201 citations2026: 2 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,031 citing papers, 23.3% of this breakdownUnited Kingdom: 1,426 citing papers, 11% of this breakdownGermany: 994 citing papers, 7.6% of this breakdownItaly: 870 citing papers, 6.7% of this breakdownFrance: 665 citing papers, 5.1% of this breakdownNetherlands: 539 citing papers, 4.1% of this breakdownChina: 479 citing papers, 3.7% of this breakdownCanada: 445 citing papers, 3.4% of this breakdownAustralia: 413 citing papers, 3.2% of this breakdownSpain: 398 citing papers, 3.1% of this breakdownSweden: 306 citing papers, 2.4% of this breakdownSwitzerland: 282 citing papers, 2.2% of this breakdown
0%23.3%Other 24.2%

Institutions

Fields

  • Medicine82.3%
  • Biochemistry, Genetics and Molecular Biology8.6%
  • Health Professions2.7%
  • Immunology and Microbiology1.5%
  • Social Sciences0.8%
  • Neuroscience0.8%
  • Other3.3%

Topics

  • Acute Myeloid Leukemia Research11.8%
  • Acute Lymphoblastic Leukemia research3.8%
  • Myeloproliferative Neoplasms: Diagnosis and Treatment3.8%
  • Chronic Myeloid Leukemia Treatments2.9%
  • Smoking Behavior and Cessation2.8%
  • Hematopoietic Stem Cell Transplantation2.7%
  • Other72.2%

Coauthors

All papers

Open in search
  1. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials

    Authors: David Grimwade, Robert K. Hills, Anthony V. Moorman, Helen M. Walker, S Chatters, Anthony H. Goldstone, Keith Wheatley, Christine J. Harrison, Alan K. Burnett - Blood 2010 cited by 1,951

  2. Mortality in relation to smoking: 40 years' observations on male British doctors

    Authors: Richard Doll, Richard Peto, Keith Wheatley, Richard Gray, I. L. G. Sutherland - BMJ 1994 cited by 5,773

  3. Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia

    Authors: Charles Craddock, Aimee Jackson, Justin Loke, Shamyla Siddique, Andrea Hodgkinson, John Mason, Georgia Andrew, Sandeep Nagra, Ram Malladi, Andrew Peniket, Maria Gilleece, Rahuman Salim, Eleni Tholouli, Victoria Potter, Charles Crawley, Keith Wheatley, Rachel Protheroe, Paresh Vyas, Ann Hunter, Anne Parker, Keith Wilson, Jiří Pavlů, Jenny Byrne, Richard Dillon, Naeem Khan, Nicholas McCarthy, Sylvie Freeman - Journal of Clinical Oncology 2020 cited by 165

  4. Rituximab for High-Risk, Mature B-Cell Non-Hodgkin’s Lymphoma in Children

    Authors: Véronique Minard‐Colin, Anne Aupérin, Marta Pillon, G.A. Amos Burke, Donald A. Barkauskas, Keith Wheatley, Rafael F. Delgado, Sarah Alexander, Anne Uyttebroeck, Catherine M. Bollard, József Zsíros, Monika Csóka, Bernarda Kazanowska, Aks Chiang, Rodney R. Miles, Andrew Wotherspoon, Peter C. Adamson, Gilles Vassal, Catherine Patte, Thomas G. Gross - New England Journal of Medicine 2020 cited by 312

  5. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial

    Authors: John A. Liu Yin, Michelle A. O'Brien, Robert K. Hills, Sarah B. Daly, Keith Wheatley, Alan K. Burnett - Blood 2012 cited by 419

  6. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials

    Authors: Panagiotis Kottaridis, Rosemary E. Gale, Marion E. Frew, G Harrison, Stephen E. Langabeer, Andrea A. Belton, Helen M. Walker, Keith Wheatley, David Bowen, Alan K. Burnett, Anthony H. Goldstone, David C. Linch - Blood 2001 cited by 1,538

  7. Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial

    Authors: Alan K. Burnett, Nigel H. Russell, Robert K. Hills, Ann E. Hunter, Lars Kjeldsen, John Liu Yin, Brenda Gibson, Keith Wheatley, Donald Milligan - Journal of Clinical Oncology 2013 cited by 415

  8. Association between premature mortality and hypopituitarism

    Authors: Jeremy Tomlinson, N Holden, Robert K. Hills, Keith Wheatley, RN Clayton, AS Bates, MC Sheppard, PM Stewart - The Lancet 2001 cited by 1,009

  9. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial

    Authors: Adrian C. Williams, Steven R. Gill, Thelekat R. K. Varma, Crispin Jenkinson, Niall Quinn, Rosalind Mitchell, Richard Scott, Natalie Ives, Caroline Rick, Jane Daniels, Smitaa Patel, Keith Wheatley - The Lancet Neurology 2010 cited by 729

  10. Efficiency and safety of varying the frequency of whole blood donation (INTERVAL): a randomised trial of 45 000 donors

    Authors: Emanuele Di Angelantonio, Simon G. Thompson, Stephen Kaptoge, Carmel Moore, Matthew R. Walker, Jane Armitage, Willem H. Ouwehand, David J. Roberts, John Danesh, Emanuele Di Angelantonio, Simon G. Thompson, Stephen Kaptoge, Carmel Moore, Matthew R. Walker, Jane Armitage, Willem H. Ouwehand, David J. Roberts, John Danesh, Jane Armitage, John Danesh, Emanuele Di Angelantonio, Jenny Donovan, Ian Ford, Rachel Henry, Beverley J. Hunt, Bridget le Huray, Susan Mehenny, Gail Miflin, Carmel Moore, Willem H. Ouwehand, Jane Green, David J. Roberts, Mike Stredder, Simon G. Thompson, Matthew R. Walker, Nicholas A. Watkins, Alan McDermott, Clive Ronaldson, Claire Thomson, Zoe Tolkien, Lorna M. Williamson, David L. Allen, John Danesh, Emanuele Di Angelantonio, Rachel Henry, Susan Mehenny, Carmel Moore, Willem H. Ouwehand, David J. Roberts, Jennifer Sambrook, Matthew R. Walker, Tracey Hammerton, Claire Thomson, Zoe Tolkien, David L. Allen, David Bruce, Fizzah Choudry, Emanuele Di Angelantonio, Cédric Ghevaert, Kirstie Johnston, Anne M. Kelly, Andrew King, Susan Mehenny, Gail Miflin, Alfred Mo, Carmel Moore, Willem H. Ouwehand, Lizanne Page, Penny Richardson, David J. Roberts, Jennifer Sambrook, Peter Senior, Yagnesh Umrania, Matthew R. Walker, Henna Wong, Stephen Kaptoge, Gavin J. Murphy, Adrian C. Newland, Keith Wheatley, M. Greaves, Marc Turner, Tahir Aziz, Richard A. Brain, Christine Davies, Ruth Turner, Paula Wakeman, Alison Dent, Alan Wakeman, Ben Anthony, Desmond Bland, Will Parrondo, Helen Vincent, Candy Weatherill, Andrea Forsyth, Carol Butterfield, Tracey Wright, Karen Ellis, Kirstie Johnston, Pat Poynton, Carolyn Brooks and 68 more - The Lancet 2017 cited by 299

  11. Bortezomib for the treatment of multiple myeloma

    Authors: Kathleen M. Scott, Patrick Hayden, Andrea Will, Keith Wheatley, Imelda Coyne - Cochrane Database of Systematic Reviews 2016 cited by 152

  12. Hydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia

    Authors: Claire Harrison, Peter J. Campbell, Georgina Buck, Keith Wheatley, Clare East, D. Bareford, Bridget S. Wilkins, Jon van der Walt, John T. Reilly, Andrew Grigg, Paul Revell, Barrie Woodcock, Anthony R. Green - New England Journal of Medicine 2005 cited by 921

  13. Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial

    Authors: Alan K. Burnett, Robert K. Hills, Donald Milligan, Lars Kjeldsen, Jonathan Kell, Nigel H. Russell, John A. Liu Yin, Ann Hunter, Anthony H. Goldstone, Keith Wheatley - Journal of Clinical Oncology 2010 cited by 652

  14. Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial

    Authors: Bernadette Brennan, Laura Kirton, Perrine Marec‐Bérard, Nathalie Gaspar, Valérie Laurence, Javier Martín‐Broto, Ana Méndez‐Echevarría, Hans Gelderblom, Cormac Owens, Nicola Fenwick, Sandra J. Strauss, V. V. Moroz, Jeremy Whelan, Keith Wheatley - The Lancet 2022 cited by 125

  15. Physiotherapy versus placebo or no intervention in Parkinson's disease

    Authors: Claire L Tomlinson, Smitaa Patel, Charmaine Meek, Clare P Herd, Carl E Clarke, Rebecca Stowe, Laila Shah, Catherine Sackley, Katherine Deane, Keith Wheatley, Natalie Ives - Cochrane Database of Systematic Reviews 2013 cited by 446

  16. Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy

    Authors: Richard Gray, Smitaa Patel, Natalie Ives, Caroline Rick, Rebecca Woolley, Sharon Muzerengi, Alastair Gray, Crispin Jenkinson, Emma McIntosh, Keith Wheatley, Adrian J. Williams, Carl E Clarke, PD MED Collaborative Group, Keith Young, Helen Price, Jonathan Price, Anne Lambert, Robin Reeve, M Sewell, Sally Broome, Adrian J. Williams, Mary Baker, Carl E Clarke, Ray Fitzpatrick, Alastair Gray, Richard Greenhall, Crispin Jenkinson, David Mant, Emma McIntosh, Peter Sandercock, Colin Baugent, Peter Crome, Pui Au, Thomas Boodell, Versha Cheed, Jane Daniels, Francis Dowling, Lorraine Evans, R J Hawker, Surinder Kaur, Caroline Rick, Keith Wheatley, Neil Winkles, David Hingley, Lauren Sturdy, Rebecca Wooley, Ryan Ottridge, Lisa Peto, Nicholas Hilken, Carl Counsell, Linda Caie, Robert Caslake, R. Coleman, Patrick M. Crowley, Linda M. Gerrie, Joanna Gordon, Clare Harris, V. Leslie, M. A. Macleod, Kate Taylor, Paul Worth, Roger A. Barker, Duncan R. Forsyth, M. Halls, John Young, Wendy Phillips, Mark Manford, N. Thangarajah, Debbie Blake, Richard Prescott, P. Carr, Lindy Cochrane, Angela Rose, Andrew McLaren, M. Drover, P. Mahinda Karunaratne, Amanda Eady, Magdalena Wislocka-Kryjak, Naveed Ghaus, A. Grueger, B. Mallinson, G. Wihl, S Ballantyne, Sharon Hutchinson, Alistair Lewthwaite, David Nicholl, Alistair Ritch, Sharon Coyle, R. W. Hornabrook, Hanan Irfan, S. Poxon, Uma Nath, James Davison, Sally Dodds, Gina Robinson, Carol Gray, Peter Fletcher, Philip Morrow, M. Sliva, Edmund Folkes and 226 more - JAMA Neurology 2021 cited by 60

  17. High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008

    Authors: Uta Dirksen, Bernadette Brennan, Marie‐Cécile Le Deley, Nathalie Cozic, Henk van den Berg, Vivek A. Bhadri, Bénédicte Brichard, L. Claude, Alan Craft, Susanne Amler, Natalie Gaspar, Hans Gelderblom, Robert E. Goldsby, Richard Görlick, Holcombe E. Grier, Jean-Marc Guinbretiere, Péter Hauser, Lars Hjorth, Katherine A. Janeway, Heribert Juergens, Ian Judson, Mark Krailo, Jarmila Kruseová, Thomas Kuehne, Ruth Ladenstein, Cyril Lervat, Stephen L. Lessnick, Ian Lewis, Claude Linassier, Perrine Marec‐Bérard, Neyssa Marina, Bruce Morland, Hélène Pacquement, Michael Paulussen, R. Lor Randall, Andreas Ranft, Gwénaël Le Teuff, Keith Wheatley, Jeremy Whelan, Richard B. Womer, Odile Oberlin, Douglas S. Hawkins, on behalf of the Euro-E.W.I.N.G. 99 and Ewing 2008 Investigators - Journal of Clinical Oncology 2019 cited by 145

  18. The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial

    Authors: David Grimwade, Helen M. Walker, Fiona Oliver, Keith Wheatley, Christine J. Harrison, G Harrison, John Rees, Ian Hann, Richard Stevens, Alan K. Burnett, Anthony P. Goldstone - Blood 1998 cited by 2,638

  19. Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy

    Authors: David Grimwade, Jelena Jovanović, Robert K. Hills, Elizabeth Nugent, Yashma Patel, Rajinder Flora, Daniela Diverio, Katy Jones, H. Aslett, Elaine Batson, Kristian Rennie, Roger Angell, Richard E. Clark, Ellen Solomon, Francesco Lo‐Coco, Keith Wheatley, Alan K. Burnett - Journal of Clinical Oncology 2009 cited by 356

  20. Clinical effectiveness and cost-effectiveness of physiotherapy and occupational therapy versus no therapy in mild to moderate Parkinson’s disease: a large pragmatic randomised controlled trial (PD REHAB)

    Authors: Carl E Clarke, Smitaa Patel, Natalie Ives, Caroline Rick, Rebecca Woolley, Keith Wheatley, Marion Walker, Shihua Zhu, Rebecca Kandiyali, Guiqing Yao, Catherine Sackley, on behalf of the PD REHAB Collaborative Group - Health Technology Assessment 2016 cited by 107

  21. Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)

    Authors: Julia Chisholm, Henry Mandeville, Madeleine Adams, Veronique Minard-Collin, Timothy Rogers, Anna Kelsey, Janet Shipley, Rick R. van Rijn, Isabelle de Vries, Roelof van Ewijk, Bart de Keizer, Susanne A. Gatz, Michela Casanova, Lisa Lyngsie Hjalgrim, Charlotte Firth, Keith Wheatley, Pamela Kearns, Wenyu Liu, Amanda Kirkham, Helen Rees, Gianni Bisogno, Ajla Wasti, Sara Wakeling, Delphine Heenen, Deborah A. Tweddle, Johannes H. M. Merks, Meriel Jenney - Cancers 2024 cited by 50

  22. Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial

    Authors: Simon Bailey, Nicolás André, Lorenza Gandola, Maura Massimino, Keith Wheatley, Simon Gates, Victoria Homer, Stefan Rutkowski, Steven C. Clifford - Cancers 2022 cited by 47

  23. A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment

    Authors: Alan K. Burnett, Donald Milligan, Archie Prentice, Anthony H. Goldstone, Mary Frances McMullin, Robert K. Hills, Keith Wheatley - Cancer 2007 cited by 616

  24. High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008

    Authors: Jeremy Whelan, Marie‐Cécile Le Deley, Uta Dirksen, Gwénaël Le Teuff, Bernadette Brennan, Nathalie Gaspar, Douglas S. Hawkins, Susanne Amler, Sebastian Bauer, Stefan Bielack, Jean‐Yves Blay, Stefan Burdach, Marie‐Pierre Castex, Dagmar Dilloo, Angelika Eggert, Hans Gelderblom, Jean‐Claude Gentet, Wolfgang Hartmann, Wolf-Achim Hassenpflug, Lars Hjorth, Marta Jimenez, Thomas Klingebiel, Udo Kontny, Jarmila Kruseová, Ruth Ladenstein, Valérie Laurence, Cyril Lervat, Perrine Marec‐Bérard, Sandrine Marréaud, Jean Michon, Bruce Morland, Michael Paulussen, Andreas Ranft, Peter Reichardt, Hendrik Van den Berg, Keith Wheatley, Ian Judson, Ian Lewis, Alan Craft, Heribert Juergens, Odile Oberlin, on behalf of the Euro-E.W.I.N.G.99 and EWING-2008 Investigators - Journal of Clinical Oncology 2018 cited by 166